Amiel Gross – The Center for Breakthrough Medicines
Amiel Gross is the Head of Legal at Center for Breakthrough Medicines. Amiel Gross handles IP matters, contracts, licensing, and partnership and sponsored research agreements. Besides managing compliance and regulatory issues, he is also in charge of human resources. He has also streamlined the company’s business operations by providing greater structure while eliminating risks “so scientists can work more efficiently.”
People rely on Amiel Gross’ expertise to spot issues they hadn’t considered, and vice versa. Together they are sculpting the company’s future.
Gross’ Daily Operations at CFBM
While working with CFBM, he has found fulfillment in “providing support for valuable projects.” He has also found his home at CFBM because of the creative freedom they offer and their dedication to research. Amiel Gross is part of a team that is building something new and exciting. There are many challenges ahead, but Amiel feels like he’s bringing something special to the table by helping create an innovative culture that is more collaborative than competitive.
Amiel Gross works on a day to day basis with his team. He has overseen the company’s technology and research partnerships, and he also manages contract negotiations. This helps ensure that the company’s future is secure by providing better legal advice.
Center for Breakthrough Medicines is not just about finding new treatments or cures. It’s about developing a culture of innovation—and Amiel Gross has done that over the years, building a highly collaborative environment where scientists can work more efficiently and effectively.
The Future Vision of Amiel Gross for CFBM
One of the most important things to Amiel Gross is providing a “winning team,” which is why he wants to form partnerships and find sponsorships. This allows them to work on their research while they bring in strategic business partners who can help them reach their goal. By providing these opportunities, Center for Breakthrough Medicine will be able to grow and achieve its mission of discovering cures for cancer and other diseases before others do.
Amiel Gross has also been working with the company’s human resources department. Partly due to his experience with many companies, he realized that there is too much risk involved when it comes to science research projects. At some point during the process, one or more scientists will leave their jobs because they don’t feel like they’re being supported by the company. He’s worked hard to eliminate this risk by providing a structure for those working at the company so that everyone can succeed without fear of being laid off mid-project.
Legal Experience
The combined legal experience of Mr. Gross at CFBM is over 20 years. Prior to this, Amiel Gross spent several years as in-house counsel for subsidiaries of a large global company and as practiced for more than a decade in the New York offices of Dentons US LLP and Orrick, Herrington & Sutcliffe LLP. Wyeth Pharmaceuticals, Lederle Labs, and American Cyanamid were among his clients in private practice.
But, Amiel was determined to do something different and more meaningful. Despite being no scientist, Gross has a natural curiosity about biotech, pharmaceuticals, rare diseases, and helping patients. According to Amiel Gross, CBM is the culmination of all the good things he encountered during his career. Each of these medicines has the potential to change the trajectory of human history, as they represent some of the most highly engineered and scientifically advanced medicines in the world. Amiel considers himself the luckiest guy in the world to be able to contribute to saving lives while practicing law.
Amiel’s Education
A native of Texas, Amiel graduated from Southwestern University in 1996 with a degree in liberal arts and competed there as an NCAA all-American baseball player. While an undergraduate at Southwestern University, Mr. Gross was an NCAA All-American collegiate baseball player, graduating with high honors and Phi Beta Kappa. Later, he earned a law degree from The University of Texas School of Law, where he was awarded an NCAA scholarship.